DERM (Journey Medical Corp) Market Value to Book Value Ratio

Official company branding of journeymedicalcorp.com (DERM)

Journey Medical (DERM) focuses on the production of proven dermatological drugs that guarantee a steady cash flow and high-quality earnings. The company is implementing advanced treatments for rosacea and acne, expanding its aesthetic presence through its distribution channels. The stock price tracked on the GURU.Markets chart is 4.28. Operations are protected by stable US law and an absence of trade restrictions, which minimizes external risks.

DERM journeymedicalcorp.com: Market Value to Book Value in the range 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for Journey Medical (DERM)

- price and consensus price forecast:
Price Chart journeymedicalcorp.com|DERM - Consensus Target
- market capitalization data:
Market Value Journey Medical Corp.|DERM - Full Business Value
- book capitalization data:
Book Value per Share Journey Medical|DERM - Accounting Value of Company|Market Capitalization to Book Value Ratio journeymedicalcorp.com|DERM - Company Total Assets
- debt and liquidity data:
Debt to Equity Journey Medical|DERM - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity journeymedicalcorp.com|DERM - Company Total Debt|Debts to Book Capitalization Journey Medical Corp.|DERM - Company Long-Term Debts|Company Current Liabilities Journey Medical
Initial company analysis:Journey Medical Corp - DERM
Original product of journeymedicalcorp.com

The Journey Medical (DERM) production outsourcing model minimizes capital expenditures by shifting risks to vendors and optimizing the asset structure. By analyzing the market capitalization-to-book value ratio, an investor determines the premium paid for the business relative to its net value, separating speculative price growth from the issuer's actual fundamental stability on this chart.

Main competitors

KRYS (Krystal Biotech, Inc.) - Market Value to Book Value Ratio|APGE (apogeetherapeutics.com) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Arcutis Biotherapeutics, Inc. ARQT|Market Capitalization to Net Assets Vericel Corp|Oruka Corp (ORKA) - Market Capitalization to Book Value Ratio|Market Value to Book Value sanaramedtech.com (SMTI)|Market Capitalization to Book Value Ratio DBVT (DBV Technologies)|Solesence Beauty - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Forte Biosciences (FBRX)|EMPG: Market Value to Book Value|SLGL (Sol-Gel) - Market Value to Book Value Ratio|AXIL Brands (AXIL) - Market Cap to Net Assets Ratio|MDCX (Medicus Pharma Ltd.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Verrica (VRCA)|Hoth Therapeutics, Inc. (HOTH) - Market Cap to Net Assets Ratio|Market Value to Book Value BFRI (biofrontera-us.com)|Market Value to Book Value Ratio VYNE|Sonoma Pharmaceuticals Inc. - Market Capitalization to Book Value|Quoin Pharma - Market Value to Book Value Ratio|AZTR - Market Capitalization to Book Value Ratio|Dermata Therapeutics, Inc. - Market Capitalization to Book Value Ratio|ELAB (Elevai Labs Inc) - Market Capitalization to Book Value|Market Value to Book Value Ratio Revance Therapeutics, Inc (RVNC)